Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DXCM
DXCM logo

DXCM Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Dexcom Inc (DXCM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
72.510
1 Day change
1.80%
52 Week Range
89.980
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Dexcom is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy, but it is also not a sell. The stock looks technically constructive and Wall Street remains mostly positive, yet the mixed analyst target moves, neutral insider/hedge fund activity, and heavy congressional selling make the setup less compelling for an impatient buyer. Since there is no strong proprietary buy signal today, the best direct call is to hold off and wait for a clearer entry rather than buy immediately.

Technical Analysis

DXCM is in a short-term uptrend with bullish moving averages (SMA_5 > SMA_20 > SMA_200), MACD histogram positive at 0.224, and RSI at 58.5, which is neutral to mildly bullish. Price closed at 75.28, just above the pivot of 74.984, suggesting the stock is holding trend support. Near-term resistance sits at 77.803 (R1) and 79.545 (R2). The technical picture is constructive, but not strong enough to justify an aggressive immediate buy after a modest move.

Options Data

Neutral
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mixed: open interest put-call ratio is balanced at 1.0, but today’s volume put-call ratio of 0.31 shows much heavier call activity than puts, which leans bullish in the short term. Total options volume is light relative to open interest, and implied volatility is moderate at 41.09 with IV rank 22.76, so the market is not pricing in a major near-term shock. Overall, options flow leans slightly bullish, but not decisively.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
7

Positive Catalysts

  • ["Stifel raised its target to $90 and maintained Buy, citing an upbeat doctor survey for the CGM market.", "Citi raised its target to $84 and kept Buy, saying med-tech fundamentals remain solid.", "Benchmark initiated Buy coverage and sees margin expansion from the G7 15 Day launch and potential reimbursement upside.", "Bernstein noted Q1 sales grew 12% organically with better-than-expected margins at 22% adjusted operating margin.", "The stock\u2019s moving averages are aligned bullishly, supporting the current trend."]

Neutral/Negative Catalysts

  • ["Barclays remains Underweight and cut its target to $64, reflecting a more cautious view.", "Several firms lowered price targets, signaling valuation and growth concerns.", "TD Cowen noted a roughly 1% U.S. growth miss fueled concern about a slowing U.S. CGM market.", "No news in the recent week means no fresh catalyst is currently driving the stock higher.", "Congress trading data shows 5 sales versus only 1 purchase, which is a cautious signal.", "Hedge funds and insiders are both neutral with no strong buying trend."]

Financial Performance

The latest financial detail available is from Q1 2026. Dexcom reported 12% organic sales growth to $1.19B, with 11% growth in the U.S. and 17% outside the U.S. Bernstein highlighted a strong 22% adjusted operating margin, which was better than expected. That points to solid growth and improving profitability in the latest quarter season, even though some analysts noted a small U.S. growth miss.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Wall Street is mostly positive but more mixed than before. Recent updates include Stifel and Citi raising price targets and keeping Buy, Benchmark initiating Buy, while BofA and Canaccord cut targets but stayed positive, and Barclays stayed negative with Underweight. The pros view is that Dexcom has solid growth, improving margins, new product catalysts, and a favorable CGM market backdrop. The cons view is that U.S. growth appears a bit softer, targets have been coming down, and some analysts see slower multiple expansion. Net-net, analysts remain broadly constructive, but enthusiasm has cooled somewhat.

Wall Street analysts forecast DXCM stock price to rise
16 Analyst Rating
Wall Street analysts forecast DXCM stock price to rise
13 Buy
2 Hold
1 Sell
Strong Buy
Current: 71.230
sliders
Low
68
Averages
82.54
High
100
Current: 71.230
sliders
Low
68
Averages
82.54
High
100
Piper Sandler
Matt O'Brien
maintain
$75 -> $88
AI Analysis
2026-06-15
New
Reason
Piper Sandler
Matt O'Brien
Price Target
$75 -> $88
AI Analysis
2026-06-15
New
maintain
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on DexCom to $88 from $75 and keeps an Overweight rating on the shares. The firm is updating a few of its models to better align with quarterly cadence, company guidance and consensus estimates. For DexCom, Piper cites greater visibility on the long-term pipeline and catalyst cadence that supports sustained, outsized top-line growth.
Stifel
Jonathan Block
Buy
maintain
$85 -> $90
2026-06-05
Reason
Stifel
Jonathan Block
Price Target
$85 -> $90
2026-06-05
maintain
Buy
Reason
Stifel analyst Jonathan Block raised the firm's price target on DexCom to $90 from $85 and keeps a Buy rating on the shares. The firm's survey of 35 doctors, with data specific to 20 Endocrinologists and 15 Primary Care Physicians, was "upbeat for the CGM market," the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DXCM
Unlock Now

People Also Watch